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Abstract
Purpose The aim of this study was to prospectively
evaluate the outcomes and the conversion ratio of switching
from oxycodone to methadone in advanced cancer patients
admitted to an acute palliative care unit.
Patients and methods A prospective study was carried out
on a cohort of consecutive sample of patients receiving
oxycodone, who were switched for different reasons mainly
because of an inconvenient balance between analgesia and
adverse effects. An initial conversion ratio between oxy-
codone and methadone was 3.3:1. Intensity of pain and
symptoms associated with opioid therapy were recorded,
and a distress score (DS) was also calculated as a sum of
symptom intensity. A successful switching was considered
when the intensity of pain and/or DS or the principal
symptom requiring switching decreased at least of 33% of
the value recorded before switching.
Results Nineteen out of 542 patients admitted to the unit in
1 year underwent a switching from oxycodone to methadone.
Almost all substitutions were successful. The prevalent
indication for opioid switching was uncontrolled pain and
adverse effects (12 patients). No significant changes between
the initial conversion ratio and final conversion ratio between
the two opioids were found.
Conclusion Switching from oxycodone to methadone is a
reliable method to improve the opioid response in advanced
cancer patients. A ratio of 3.3 appears to be reliable, even at
high doses. Further studies should be performed to confirm
these results in other settings and with very high doses of
oxycodone.
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Introduction
Oxycodone has been shown to be as versatile and flexible
as oral morphine in the management of cancer pain.
Controlled-release oxycodone is widely accepted as an
alternative to morphine, resulting as safe and effective as
controlled-release morphine [11], and is the preferred drug
for switching from morphine in UK [12]. Oxycodone was
efficacious and well tolerated as a first-line opioid in doses
of 20–40 mg/day after 3 weeks [14]. The use of relatively
high doses of oxycodone in terminal cancer patients was
found to be safe, efficient, and unrelated to shorter survival
times [1, 7].
Opioid substitution has been found to produce an
improvement in the opioid response [3]. Given the
increasing use of oxycodone, even at high doses, it is
likely that some patients may not respond and require an
opioid switching. Previous studies have shown outcomes
and conversion ratios between morphine, hydromorphone,
S. Mercadante (*) : P. Ferrera : P. Villari :C. Adile
Pain Relief and Palliative Care Unit,
La Maddalena Cancer Center,
Via San Lorenzo 312,
90146 Palermo, Italy
e-mail: terapiadeldolore@lamaddalenanet.it
S. Mercadante
e-mail: 03sebelle@gmail.com
S. Mercadante
Palliative Medicine, University of Palermo,
Palermo, Italy
A. Casuccio
Department of Experimental Biomedicine and Clinical
Neuroscience, University of Palermo,
Palermo, Italy
Support Care Cancer (2012) 20:191–194
DOI 10.1007/s00520-011-1259-9
and transdermal fentanyl [8]. However, switching from
oxycodone to methadone has never been assessed and an
indirect conversion ratio with morphine has been used in
some circumstances [9]. The aim of this study was to assess
the outcome and the final conversion ratio between
oxycodone and methadone.
Patients and methods
A prospective study was carried out in a sample of
consecutive patients admitted to an acute palliative care
unit for a period of 1 year. Informed consent (from relatives
in case of cognitive failure) and institutional approval were
obtained. Advanced cancer patients receiving oxycodone
who were required to switch opioid therapy were included
in four categories:
(a) Patients presenting relevant adverse effects despite
good pain control; to be switched, patients had to
present at least one relevant symptom, such as
drowsiness, confusion, or myoclonus with intensity=
2 on a scale from 0 to 3 (see below), or other
symptoms (constipation, dry mouth) rated as severe
(b) Patients with a poor analgesic response despite having
their dose doubled in 1 week
(c) Patients with both poor pain control and prevalent
adverse effects
(d) Patients who were switched for patient’s preference
and/or convenience (example dysphagia limiting the
oral route) or other reasons (renal failure)
The scenario was that of a clinical setting of an intensive
acute palliative care unit. Intravenous methadone was used
when the oral tract was unavailable. Rescue doses of
methadone were used, intravenously or orally, using the
equivalent of one sixth of the daily dose, to support the
switching. According to previous experience, based on an
indirect conversion from oral morphine to oral methadone
[9], the initial conversion ratio was oral methadone 20=
intravenous methadone 16=oral oxycodone 70 (oral
oxycodone–oral methadone ratio approximately 3.5:1).
According a “stop and go” approach previously described
with morphine, oxycodone was stopped and methadone was
given immediately, being the daily dose calculated divided in
three administrations [10]. After the initial dose, the
subsequent doses were flexible and were changed timely to
fit the patients’ needs in an attempt to find the best balance
between pain and opioid-related symptoms.
Adjuvant drugs, previously administered to control
symptoms due to illness or treatment, were continued at
the same doses during the switching. Non-opioid analgesics
were also continued if previously administered at the same
doses. No patient received anticancer therapy during the
course of the study. All patients were strictly monitored by
a team consisting of doctors and nurses experienced in
palliative care. In particular, pain and symptoms are
recorded in a sheet by nurses four times a day, as a routine,
and four rounds or more are performed by the team to
explore clinical changes. A physician on duty and a team
component on call were available. Daily doses were
changed, according to the amount of drugs consumed as
rescue doses in the previous day and the clinical judgment,
to achieve the best clinical balance between analgesia and
adverse effects.
The following data were recorded:
– Age, gender, primary cancer, and performance status
– Pain intensity, measured using the patient’s self report
on a numerical 0–10 scale
– Symptoms associated with opioid therapy or commonly
present in advanced cancer patients, such as nausea and
vomiting, drowsiness, confusion, constipation, dry
mouth, myoclonus, sweating, using a scale from 0 to
3, corresponding to a verbal scale (not at all, slight, a
lot, awful), were recorded. A distress score (DS) was
also calculated as a sum of symptom intensity.
Although never validated, this score has been previ-
ously used in different studies for determining the
“weight” of adverse effects. The aim of using a sum of
intensities is justified by the high variability of
symptom intensity requiring opioid substitution in
individual patients. This score is able to determine a
general improvement of symptoms. The evaluation of
the changes in the intensity of a single symptom,
different for each patient, makes a global evaluation
and statistics for a group of patients, practically
impossible. Moreover, it is not rare to switch a patient
for more than one symptom. Changes in DS have been
already used to assess outcomes of switching [9]. On
the other hand, an important decrease of the principal
symptom which required the switching is another
parameter to take into consideration. Thus, these
Table 1 Characteristics of patients
Gender (m/f) 13/4
Age (years) 65.9 (9.1)
Cancer diagnosis
Lung 7
Breast 3
Prostate 2
Others 7
Karnofsky status 46.5 (4.9)
Time from switching to hospital discharge (days) 4.7 (1.7)
Time to achieve stabilization (days) 3.4 (1.8)
Mean values (±SD)
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parameters were used to define a successful switching
(see above). Symptoms were assessed by the patient,
whenever possible. However, in patients who had
severe cognitive failure, a proxy evaluation was taken
into account.
The following parameters and intervals were recorded:
daily opioid doses, pain intensity, and DS before switching
(T0), at 24-h intervals for 3 days, and at time of stabilization
which is the time to reach a stable daily dose considered as
the first of two consecutive days requiring no more than
two rescue doses (T end) and time from admission to
hospital discharge (T discharge). Data were analyzed using
the paired Wilcoxon signed-rank test to compare opioid
dosage, pain intensity scores, and symptom intensity scores
in the different time intervals. Spearman’s rho correlation
coefficient was calculated to measure the strength of the
relationship between the previous dose of oxycodone and
the methadone dosage at discharge. All p values were two
sided, and p values less than 0.05 were considered to
indicate statistical significance.
Results
Nineteen out of 542 patients admitted to the unit in 1 year
underwent a switching from oxycodone to methadone, and
one patient was switched from methadone to oxycodone (not
considered for analysis). The characteristics of patients are
presented in Table 1. Almost all substitutions were success-
ful. One patient was discharged before achieving adequate
stabilization on request of the relatives. One patient could not
appropriately be assessed because he was severely ill and
required palliative sedation before dying. The indications for
opioid switching were uncontrolled pain and adverse effects
(12 patients), adverse effects (3 patients), uncontrolled pain
(3 patients), and renal failure (n=1).
No significant changes between the initial conversion ratio
and final conversion ratio between the two opioids were found
(see Table 2). A significant correlation between oxycodone
doses and final methadone doses was found (Spearman’s rho
correlation coefficient=0.945; p<0.01), but not between
oxycodone doses and final conversion ratio (see Fig. 1).
Discussion
In this study, the switching from oxycodone to methadone
was successful in the majority of patients. The indirect
conversion ratio used to start the daily dose of methadone
did not change, confirming the reliability of the ratio
chosen. Of interest, the higher oxycodone dose, the higher
methadone dose was found, with a correlation between
opioid doses. On the other hand, no correlation between
oxycodone doses and final conversion ratio was found.
The most controversial drug for opioid switching is
methadone, and the vast majority of studies focused on
switching from different opioids to methadone. The
advantages of using methadone for refractory pain or
adverse effects with other opioids have been invariably
reported in literature [8]. The absence of known metabolites
allowing a safe use with renal failure, extra-opioid activity
on NMDA receptor system, and low cost are the positive
Table 2 Data of patients who completed the switching from oxycodone to methadone successfully at the different intervals considered
T0 T (24 h) T (48 h) T (72 h) T end
Oxycodone 305.9 (249.1)
Methadone 86.1 (78.0) 91.8 (88.5) 88.0 (81.2) 93.8 (89.2) 88.6 (77.8)
Pain 6.6 (1.7) 3.7 (1.2)*, ** 2.8 (1.3)*, ** 2.8 (1.2)*, ** 2.6 (1.0)*, **
DS 4.5 (1.2) 3.1 (1.2)*** 2.9 (1.0)*** 2.9 (0.7)*** 2.7 (1.0)***
Data are expressed as a mean (±SD)
DS distress score
*p<0.0005 vs T0; **p=0.005 vs 24 h; ***p=0.001 vs T0
Fig. 1 Plot of oxycodone doses and final conversion ratio
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characteristics of this agent. However, methadone has major
pharmacokinetic and pharmacodynamic differences capable
of making the switching more complex. Specifically, the
lack of reliable equianalgesic conversion ratios, increased
potency associated with methadone in patients previously
exposed to high-dose opioids, large interindividual vari-
ability in methadone pharmacokinetics, and the potential
for pharmacological interaction with other drugs have made
the clinical use of methadone difficult.
Systematic reviews on switching to methadone have
shown a large heterogeneity in terms of opioid ratios,
outcomes, and modality of switching utilized [4, 5, 10, 15,
16]. The dose of methadone cannot be easily predicted as it
will depend on a series of factors, including individual
response, pharmacodynamics, pain mechanism, pharmaco-
genetics, and degree of cross-tolerance [4].
Data regarding the switching from oxycodone are lacking,
and conversion ratios have never been assessed in specific
studies, unless one utilizes indirect conversion ratios through
morphine equivalents [9]. In this previous survey, an
approximate ratio of 3.3 was found. These data were
confirmed in this selective study on opioid switching from
oxycodone to methadone, differently from studies of
morphine–methadone switching, where there was a correla-
tion between the previous dose of morphine and the final
ratio, particularly in patients receiving high doses of
morphine [2, 6, 13]. In this study, the doses of oxycodone
were in the medium range of clinical dosages (extremes 20–
960 mg/day), so that this approach should be better assessed
in patients receiving very high doses of oxycodone. In this
study, seven patients were receiving doses of ≥300 mg/day,
but the conversion ratio was not different from patients
receiving lower doses, although the number of patients
cannot be considered sufficient to provide definitive data.
The principal limitation is represented by the low number of
patients included in this study, which however, represent a
discrete amount of patients recruited in an acute palliative
care unit during a 1-year period, where a consistent number
of opioid substitutions are performed [9].
In conclusion, switching from oxycodone to methadone is
a reliable method to improve the opioid response in advanced
cancer patients. A ratio of 3.3 appears to be reliable even at
relatively high doses. However, these data were obtained in an
intensive palliative care unit, with a high level of monitoring,
and should be considered as preliminary. Further studies
should be performed to confirm these results in other settings
and with very high doses of oxycodone.
Conflicts of interest There is no conflict of interest.
References
1. Bercovitch M, Adunsky A (2006) High dose controlled-release
oxycodone in hospice care. J Pain Palliat Care Pharm 20:33–39
2. Bruera E, Pereira J, Watanabe S et al (1996) Opioid rotation in
patients with cancer pain. A retrospective comparison of dose
ratios between methadone, hydromorphone, and morphine.
Cancer 78:852–857
3. Expert Working Group of the European Association of Palliative
Care Network, Cherny N, Ripamonti C, Pereira J, Davis C, Fallon
M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001)
Strategies to manage the adverse effects of oral morphine: an
evidence-based report. J Clin Oncol 19:2542–2554
4. Fine PG, Portenoy RK (2009) Establishing best practices for
opioid rotation: conclusions of an expert panel. J Pain Symptom
Manage 38:418–425
5. Knotkova H, Fine P, Portenoy RK (2009) Opioid rotation: the
science and the limitations of the equianalgesic dose table. J Pain
Symptom Manage 38:426–439
6. Lawlor P, Turner K, Hanson J, Bruera E (1998) Dose ratio
between morphine and methadone in patients with cancer pain: a
retrospective study. Cancer 82:1167–1173
7. Mercadante S, Ferrera P, David F, Casuccio A (2011) The use of
high doses of oxycodone in an acute palliative care unit. Am J
Hosp Pall Care 28:242–244
8. Mercadante S, Bruera E (2006) Opioid switching: a systematic
and critical review. Cancer Treat Rev 32:304–315
9. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G,
Mangione S (2009) Frequency, indications, outcomes, and
predictive factors of opioid switching in an acute palliative care
unit. J Pain Symptom Manage 37:632–641
10. Mercadante S, Casuccio A, Calderone L (1999) Rapid switching
from morphine to methadone in cancer patients with poor
response to morphine. J Clin Oncol 17:3307–3312
11. Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW (2006)
Oxycodone for cancer-related pain: meta-analysis of randomized
controlled trials. Arch Intern Med 166:837–843
12. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R,
Welsh K (2006) No pain relief from morphine? Individual
variation in sensitivity to morphine and the need to switch to
an alternative opioid in cancer patients. Support Care Cancer
14:56–64
13. Ripamonti C, Groff L, Brunelli C et al (1998) Switching from
morphine to oral methadone in treating cancer pain: what is the
equianalgesic dose ratio? J Clin Oncol 16:3216–3221
14. Silvestri B, Bandieri E, Del prete S et al (2008) Oxycodone
controlled-release as first choice therapy for moderate-to-severe
cancer pain in Italian patients. Clin Drug Invest 28:399–407
15. Slatkin N (2009) Opioid switching and rotation in primary care:
implementation and clinical utility. Curr Med Res Opin 25:2133–
2159
16. Weschules D, Bain K (2008) A systematic review of opioid
conversion ratios used with methadone for the treatment of pain.
Pain Med 9:595–612
194 Support Care Cancer (2012) 20:191–194
